Clinical Challenges

The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer

Ximena DeCaire

Erin Streu

ambulatory care/office nursing, biotherapy/targeted therapies, clinical practice, lung cancer
ONF 2016, 43(5), 544-547. DOI: 10.1188/16.ONF.544-547

The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the advent of targeted therapy and changed the clinical landscape. ROS1 is a rare driver mutation found in 1%–2% of patients diagnosed with NSCLC. This case highlights a young woman of Asian descent with no history of smoking diagnosed with NSCLC and ROS1 rearrangement and discusses the implications for oncology nurses in clinical practice.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.